TrialScientific reports2023

Results of a phase Ib study of SB-121, an investigational probiotic formulation, a randomized controlled trial in participants with autism spectrum disorder.

Lauren M Schmitt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.